TMCnet News

Intellia Therapeutics to Present at 35th Annual Cowen and Company Healthcare Conference
[February 26, 2015]

Intellia Therapeutics to Present at 35th Annual Cowen and Company Healthcare Conference


Intellia Therapeutics, founded to develop therapeutic products using CRISPR/Cas9 technology for gene editing and repair, announced today that Nessan Bermingham, PhD, Intellia's Chief Executive Officer, will be presenting at the 35th Annual Cowen and Company Health Care Conference.

Dr. Bermingham's presentation will highlight CRISPR/Cas9 geneediting technology and its potential as a therapeutic application, as well as Intellia's progress in advancing lead programs toward the clinic. The presentation will take place on Tuesday, March 3, 2015 at 1:30 PM ET at the Marriott Copley in Boston, Mass.



About Intellia Therapeutics

Intellia Therapeutics was formed in 2014 to develop curative medicines, utilizing the promise of the CRISPR/Cas9 technology. Intellia holds exclusive access to one of the broadest intellectual property platforms available for the therapeutic use of CRISPR/Cas9. Intellia is backed by Atlas Venture and Novartis Institutes for Biomedical Research. In January of this year, Intellia Therapeutics announced a large partnering deal with Novartis for CAR-T and HSC applications of the technology. For more information, please visit intelliatx.com.



[ Back To TMCnet.com's Homepage ]